Top Markets
Coin of the day
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.

CANF
Clasificación en acciones #40868
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical... Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Precio por acción
$1.63
Capitalización bursátil
$70.02K
Cambio (1 día)
-2.11%
Cambio (1 año)
-81.59%
País
IL
Comercio Can-Fite BioPharma Ltd. (CANF)

Categoría

Historial del precio de la acción de Can-Fite BioPharma Ltd. (CANF)
Precio más alto de cierre: $1.66 el 2026-08-01

Precio más bajo de cierre: $24.37K el 2005-10-01
Historial del precio de la acción de Can-Fite BioPharma Ltd. desde 2005 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -49.64%
2025 -43.75%
2024 -24.49%
2023 -71.44%
2022 -41.01%
2021 -30.93%
2020 -44.45%
2019 -81.47%
2018 -15.17%
2017 -35.77%
2016 -28.43%
2015 -18.01%
2014 -43.11%
2013 45.74%
2012 -26.76%
2011 -36.90%
2010 11.80%
2009 153.06%
2008 -65.95%
2007 -25.91%
2006 -8.50%
2005 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$522.59 31.99%
US
$863.65 33.57%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE